Plus Therapeutics announced on August 14, 2025, positive data from a retrospective analysis of the CNSide Cerebrospinal Fluid (CSF) Assay Platform. The data was presented at the 2025 Society for Neuro-Oncology (SNO)/American Society of Clinical Oncology (ASCO) CNS Metastases Conference in Baltimore, Maryland.
The analysis, which included 613 CNSide assays from 218 individual patients, demonstrated that CNSide can quantify leptomeningeal metastases (LM) over time. It also monitors changes in the expression of multiple targetable mutations, providing therapeutic insights.
The data builds upon previous results from the FORESEE study, which showed the CNSide CSF Assay platform influenced clinical management decisions in over 90% of LM cases. It also demonstrated 2.8 times the diagnostic sensitivity versus standard CSF cytology.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.